Verastem Inc VSTM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/22/24 EDT
9.74UNCH (UNCH)
Volume
560
Close
9.74UNCH (UNCH)
Volume
94,920
52 week range
4.26 - 15.18
Loading...
  • Open9.84
  • Day High10.00
  • Day Low9.67
  • Prev Close9.74
  • 52 Week High15.18
  • 52 Week High Date05/30/23
  • 52 Week Low4.26
  • 52 Week Low Date04/26/23

Key Stats

  • Market Cap246.497M
  • Shares Out25.31M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.59
  • YTD % Change19.66

KEY STATS

  • Open9.84
  • Day High10.00
  • Day Low9.67
  • Prev Close9.74
  • 52 Week High15.18
  • 52 Week High Date05/30/23
  • 52 Week Low4.26
  • 52 Week Low Date04/26/23
  • Market Cap246.497M
  • Shares Out25.31M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.59
  • YTD % Change19.66

RATIOS/PROFITABILITY

  • EPS (TTM)-14.41
  • P/E (TTM)-0.68
  • Fwd P/E (NTM)-2.55
  • EBITDA (TTM)-91.824M
  • ROE (TTM)-166.79%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,843.30%
  • Debt To Equity (MRQ)51.04%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Verastem Inc

 

Profile

MORE
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both...
Daniel Paterson
President, Chief Executive Officer, Director
Daniel Calkins
Chief Financial Officer, Controller
Address
117 Kendrick Street, Suite 500
Cambridge, MA
02494
United States

Top Peers

SYMBOLLASTCHG%CHG
PYXS
Pyxis Oncology Inc
4.53UNCHUNCH
HUMA
Humacyte Inc
3.70UNCHUNCH
BDTX
Black Diamond Therapeutics Inc
5.02UNCHUNCH
ATNM
Actinium Pharmaceuticals Inc
7.17UNCHUNCH
ACRV
Acrivon Therapeutics Inc
9.51UNCHUNCH